Loading...
XNYSFMS
Market cap13bUSD
Dec 23, Last price  
22.68USD
1D
-0.57%
1Q
8.88%
Jan 2017
-46.27%
Name

Fresenius Medical Care AG & Co KGaA

Chart & Performance

D1W1MN
XNYS:FMS chart
P/E
12.82
P/S
0.33
EPS
1.70
Div Yield, %
4.94%
Shrs. gr., 5y
-13.74%
Rev. gr., 5y
3.29%
Revenues
19.45b
+0.29%
4,594,272,5155,717,514,4996,439,636,1026,666,871,7637,623,256,1037,850,289,0469,063,019,1319,872,028,54310,434,945,23110,580,072,09813,019,603,52015,309,579,08017,030,495,24017,784,000,00016,547,000,00017,477,000,00017,859,000,00017,619,000,00019,398,000,00019,453,617,000
Net income
499m
-25.90%
296,545,884384,120,523406,687,076491,857,953587,319,812621,978,678735,746,932826,448,868897,393,757803,760,140859,366,200941,185,1401,181,894,1201,280,000,0001,982,000,0001,200,000,0001,164,377,000969,308,000673,405,000498,997,000
CFO
2.63b
+21.31%
610,683,224565,944,370687,853,712822,751,819730,119,339934,568,4401,028,693,1871,115,661,3001,541,817,0961,473,565,0841,530,411,9601,792,733,6002,034,797,6002,192,000,0002,062,000,0002,567,000,0004,233,000,0002,489,000,0002,167,000,0002,628,801,000
Dividend
May 17, 20240.68831 USD/sh
Earnings
Feb 18, 2025

Profile

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
URL
https://www.freseniusmedicalcare.com/
IPO date
Oct 02, 1996
Employees
124,295
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
19,453,617
0.29%
19,398,000
10.10%
17,619,000
-1.34%
Cost of revenue
14,760,582
14,317,000
12,763,000
Unusual Expense (Income)
NOPBT
4,693,035
5,081,000
4,856,000
NOPBT Margin
24.12%
26.19%
27.56%
Operating Taxes
300,557
325,000
353,000
Tax Rate
6.40%
6.40%
7.27%
NOPAT
4,392,478
4,756,000
4,503,000
Net income
498,997
-25.90%
673,405
-30.53%
969,308
-16.75%
Dividends
(328,623)
(395,556)
(392,455)
Dividend yield
2.96%
4.40%
2.06%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,561,562
2,036,900
2,585,000
Long-term debt
14,634,796
15,854,435
15,484,000
Deferred revenue
9,474
(868,452)
Other long-term liabilities
2,502,833
1,716,379
2,395,000
Net debt
13,576,368
15,673,841
15,664,078
Cash flow
Cash from operating activities
2,628,801
2,167,000
2,489,000
CAPEX
(684,596)
(1,411,000)
(1,683,000)
Cash from investing activities
(544,227)
(734,725)
(1,196,228)
Cash from financing activities
(1,858,529)
(1,617,360)
(1,024,382)
FCF
431,592
4,250,819
4,209,477
Balance
Cash
1,539,778
1,443,770
1,618,017
Long term investments
1,080,212
773,724
786,905
Excess cash
1,647,309
1,247,594
1,523,972
Stockholders' equity
11,446,204
12,076,380
11,087,761
Invested Capital
27,732,471
28,871,964
27,036,445
ROIC
15.52%
17.01%
17.27%
ROCE
15.97%
16.36%
16.50%
EV
Common stock shares outstanding
293,413
293,246
293,065
Price
37.82
23.43%
30.64
-52.80%
64.92
-21.90%
Market cap
11,096,897
23.50%
8,985,071
-52.77%
19,025,791
-22.22%
EV
25,879,539
26,118,638
35,970,123
EBITDA
6,445,006
6,919,363
6,479,676
EV/EBITDA
4.02
3.77
5.55
Interest
424,640
360,000
353,000
Interest/NOPBT
9.05%
7.09%
7.27%